Kyle J. Trageser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kyle J. Trageser has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Giulio Maria Pasinetti
Department of Neurology, Icahn School of Medicine at Mount Sinai
9 shared publications Chad Smith
Icahn School of Medicine at Mount Sinai
7 shared publicationsEmma Zeng
Icahn School of Medicine at Mount Sinai
2 shared publicationsFrancis J. Herman
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, USA
2 shared publicationsGiulio Maria Pasinetti
Icahn School of Medicine at Mount Sinai New York NY USA
2 shared publicationsHenry Wu
Icahn School of Medicine at Mount Sinai
2 shared publications
Latest Publications
- Open Access
- 27 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (23) , 5975-5987
Peripheral human red blood cell development in human immune system mouse model with heme oxygenase-1 deficiency
A challenge for human immune system (HIS) mouse models has been the lack of human red blood cell (hRBC) survival after engraftment of these immune-deficient mice with human CD34+ hematopoietic stem cells (HSCs). This limits the use of HIS models for preclinical testing of targets directed at hRBC-related diseases. Although human white blood cells can develop in the peripheral blood of mice engrafted with human HSCs, peripheral hRBCs are quickly phagocytosed by murine macrophages upon egress from the bone marrow. Genetic ablation of murine myeloid cells results in severe pathology in resulting mice, rendering such an approach to increase hRBC survival in HIS mice impractical. Heme oxygenase-1 (HMOX-1)–deficient mice have reduced macrophages due to toxic buildup of intracellular heme upon engulfment of RBCs, but do not have an overall loss of myeloid cells. We took advantage of this observation and generated HMOX-1–/– mice on a humanized M-CSF/SIRPα/CD47 Rag2–/– IL-2Rγ–/– background. These mice have reduced murine macrophages but comparable levels of murine myeloid cells to HMOX-1+/+ control mice in the same background. Injected hRBCs survive longer in HMOX-1–/– mice than in HMOX-1+/+ controls. Additionally, upon human HSC engraftment, hRBCs can be observed in the peripheral blood of HMOX-1–/– humanized M-CSF/SIRPα/CD47 Rag2–/– IL-2Rγ–/– mice, and hRBC levels can be increased by treatment with human erythropoietin. Given that hRBC are present in the peripheral blood of engrafted HMOX-1–/– mice, these mice have the potential to be used for hematologic disease modeling, and for testing therapeutic treatments for hRBC diseases in vivo.
- 27 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (23) , 5975-5987
Open AccessPeripheral human red blood cell development in human immune system mouse model with heme oxygenase-1 deficiency
A challenge for human immune system (HIS) mouse models has been the lack of human red blood cell (hRBC) survival after engraftment of these immune-deficient mice with human CD34+ hematopoietic stem cells (HSCs). This limits the use of HIS models for preclinical testing of targets directed at hRBC-related diseases. Although human white blood cells can develop in the peripheral blood of mice engrafted with human HSCs, peripheral hRBCs are quickly phagocytosed by murine macrophages upon egress from the bone marrow. Genetic ablation of murine myeloid cells results in severe pathology in resulting mice, rendering such an approach to increase hRBC survival in HIS mice impractical. Heme oxygenase-1 (HMOX-1)–deficient mice have reduced macrophages due to toxic buildup of intracellular heme upon engulfment of RBCs, but do not have an overall loss of myeloid cells. We took advantage of this observation and generated HMOX-1–/– mice on a humanized M-CSF/SIRPα/CD47 Rag2–/– IL-2Rγ–/– background. These mice have reduced murine macrophages but comparable levels of murine myeloid cells to HMOX-1+/+ control mice in the same background. Injected hRBCs survive longer in HMOX-1–/– mice than in HMOX-1+/+ controls. Additionally, upon human HSC engraftment, hRBCs can be observed in the peripheral blood of HMOX-1–/– humanized M-CSF/SIRPα/CD47 Rag2–/– IL-2Rγ–/– mice, and hRBC levels can be increased by treatment with human erythropoietin. Given that hRBC are present in the peripheral blood of engrafted HMOX-1–/– mice, these mice have the potential to be used for hematologic disease modeling, and for testing therapeutic treatments for hRBC diseases in vivo.
- Open Access
Inflammasome mediated neuronal-microglial crosstalk: a therapeutic substrate for the familial C9orf72 variant of the frontotemporal dementia/amyotrophic lateral sclerosis
Intronic G 4 C 2 hexanucleotide repeat expansions (HRE) of C9orf72 are the most common cause of familial variants of frontotemporal dementia/amyotrophic lateral sclerosis (FTD/ALS). G 4 C 2 HREs in C9orf72 undergo non-canonical repeat-associated translation, producing dipeptide repeat (DPR) proteins, with various deleterious impacts on cellular homeostasis. While five different DPRs are produced, poly(glycine-arginine) (GR) is amongst the most toxic and is the only DPR to accumulate in the associated clinically relevant anatomical locations of the brain. Previous work has demonstrated the profound effects of a poly(GR) model of C9orf72 FTD/ALS, including motor impairment, memory deficits, neurodegeneration, and neuroinflammation. Neuroinflammation is hypothesized to be a driving factor in the disease course; microglia activation is present prior to symptom onset and persists throughout the disease. Here, using an established mouse model of C9orf72 FTD/ALS we investigate the contributions of the nod-like receptor pyrin-containing 3 (NLRP3) inflammasome in the pathogenesis of FTD/ALS. We find that inflammasome-mediated neuroinflammation is increased with microglial activation, cleavage of caspase-1, production of IL-1β and upregulation of Cxcl10 in the brain of C9orf72 FTD/ALS mice. Excitingly, we find that genetic ablation of Nlrp3 significantly improved survival, protected behavioral deficits and prevented neurodegeneration suggesting a novel mechanism involving HRE-mediated induction of innate immunity. The findings provide experimental evidence of the integral role of HRE in inflammasome-mediated innate immunity in the C9orf72 variant of FTD/ALS pathogenesis and suggest the NLRP3 inflammasome as a therapeutic target.
Open AccessInflammasome mediated neuronal-microglial crosstalk: a therapeutic substrate for the familial C9orf72 variant of the frontotemporal dementia/amyotrophic lateral sclerosis
Intronic G 4 C 2 hexanucleotide repeat expansions (HRE) of C9orf72 are the most common cause of familial variants of frontotemporal dementia/amyotrophic lateral sclerosis (FTD/ALS). G 4 C 2 HREs in C9orf72 undergo non-canonical repeat-associated translation, producing dipeptide repeat (DPR) proteins, with various deleterious impacts on cellular homeostasis. While five different DPRs are produced, poly(glycine-arginine) (GR) is amongst the most toxic and is the only DPR to accumulate in the associated clinically relevant anatomical locations of the brain. Previous work has demonstrated the profound effects of a poly(GR) model of C9orf72 FTD/ALS, including motor impairment, memory deficits, neurodegeneration, and neuroinflammation. Neuroinflammation is hypothesized to be a driving factor in the disease course; microglia activation is present prior to symptom onset and persists throughout the disease. Here, using an established mouse model of C9orf72 FTD/ALS we investigate the contributions of the nod-like receptor pyrin-containing 3 (NLRP3) inflammasome in the pathogenesis of FTD/ALS. We find that inflammasome-mediated neuroinflammation is increased with microglial activation, cleavage of caspase-1, production of IL-1β and upregulation of Cxcl10 in the brain of C9orf72 FTD/ALS mice. Excitingly, we find that genetic ablation of Nlrp3 significantly improved survival, protected behavioral deficits and prevented neurodegeneration suggesting a novel mechanism involving HRE-mediated induction of innate immunity. The findings provide experimental evidence of the integral role of HRE in inflammasome-mediated innate immunity in the C9orf72 variant of FTD/ALS pathogenesis and suggest the NLRP3 inflammasome as a therapeutic target.
- Open Access
- 27 April 2021
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 12
Editorial: Psychiatric Disorder in Veterans
Editorial: Psychiatric Disorder in Veterans
- 27 April 2021
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 12
Open AccessEditorial: Psychiatric Disorder in Veterans
Editorial: Psychiatric Disorder in Veterans
- Open Access
- 14 January 2021
- Published by Springer Nature in Translational Psychiatry
- Vol. 11 (1) , 1-15
Anxiolytic effects of NLRP3 inflammasome inhibition in a model of chronic sleep deprivation
Sleep deprivation is a form of stress that provokes both inflammatory responses and neuropsychiatric disorders. Because persistent inflammation is implicated as a physiological process in anxiety disorders, we investigated the contributions of NLRP3 inflammasome signaling to anxiety and anxiolytic properties of flavanol diets in a model of chronic sleep deprivation. The results show a flavanol-rich dietary preparation (FDP) exhibits anxiolytic properties by attenuating markers of neuroimmune activation, which included IL-1β upregulation, NLRP3 signaling, and microglia activation in the cortex and hippocampus of sleep-deprived mice. Production of IL-1β and NLRP3 were critical for both anxiety phenotypes and microglia activation. Individual FDP metabolites potently inhibited IL-1β production from microglia following stimulation with NLRP3-specific agonists, supporting anxiolytic properties of FDP observed in models of sleep deprivation involve inhibition of the NLRP3 inflammasome. The study further showed sleep deprivation alters the expression of the circadian gene Bmal1, which critically regulated NLRP3 expression and IL-1β production.
- 14 January 2021
- Published by Springer Nature in Translational Psychiatry
- Vol. 11 (1) , 1-15
Open AccessAnxiolytic effects of NLRP3 inflammasome inhibition in a model of chronic sleep deprivation
Sleep deprivation is a form of stress that provokes both inflammatory responses and neuropsychiatric disorders. Because persistent inflammation is implicated as a physiological process in anxiety disorders, we investigated the contributions of NLRP3 inflammasome signaling to anxiety and anxiolytic properties of flavanol diets in a model of chronic sleep deprivation. The results show a flavanol-rich dietary preparation (FDP) exhibits anxiolytic properties by attenuating markers of neuroimmune activation, which included IL-1β upregulation, NLRP3 signaling, and microglia activation in the cortex and hippocampus of sleep-deprived mice. Production of IL-1β and NLRP3 were critical for both anxiety phenotypes and microglia activation. Individual FDP metabolites potently inhibited IL-1β production from microglia following stimulation with NLRP3-specific agonists, supporting anxiolytic properties of FDP observed in models of sleep deprivation involve inhibition of the NLRP3 inflammasome. The study further showed sleep deprivation alters the expression of the circadian gene Bmal1, which critically regulated NLRP3 expression and IL-1β production.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S9)
Brain bioavailable microbiome derived flavonoid metabolite attenuates neuroinflammation in C9orf72 associated frontotemporal dementia
Background: Familial frontotemporal dementia (FTD) has been associated with mutations in the G4C2 promoter of C9orf72 leading to production of dipeptide protein repeats (DPRs), the most neurotoxic being Glycine‐Arginine (GR). Previous studies have found a parallel relationship with the accumulation of DPRs and a neuroinflammatory response. Specifically, studies have determined microglia proliferation and persistent activation plays a role in disease progression and neurodegeneration. The current study investigated the effect of the bioavailable microbiome derived flavonol metabolite, 3‐hydroxybenzoic acid (3‐HBA) (Wang D. et al, 2015), on microglia morphology and proliferation in mice harboring the AAV9‐GFP(GR)100 virus in the brain recapitulating FTD type neuropathology and behavior.Method: Mice were divided into three groups: GFP control, GR100, and GR100 with 3‐HBA. The GFP control group was transfected with AAV9‐GFP through intra‐cerebroventricular injection, whereas the other two groups were transfected with AAV9‐GFP(GR)100. The virus was administered on postnatal day 0, and the treatment of 3‐HBA began on day 28 for a period of 10 weeks. Immunofluorescence staining of microglia was performed on sections spanning the prelimbic/infralimbic cortex, primary somatosensory cortex (S1), and the hippocampus in order to stereologically quantify microglia proliferation and to reconstruct the microglia in 3D using the imaging software Imaris.Result: Stereological counting determined an increase in microglia density of approximately 40% (p < 0.05) in the S1 of mice transfected with AAV9‐GFP(GR)100. In addition, there was approximately 30% (p < 0.0001) reduction in S1, and hippocampal volume in groups transfected with AAV9‐GFP(GR)100. 3D reconstruction and Sholl analysis determined a change in microglia morphology from a surveilling state, as seen in the GFP control group, to that of activation characterized by increased branching closer to the soma, as observed in the GR100 group. This increased complexity/activation was found to be attenuated with the administration of 3‐HBA which was associated with a significant reduction in branch complexity compared to both the control and GR100 group.Conclusion: This study identifies a novel microbiome derived polyphenol that displayed potential in attenuating microglia activation, and hence reducing the neuroinflammatory response in FTD.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S9)
Brain bioavailable microbiome derived flavonoid metabolite attenuates neuroinflammation in C9orf72 associated frontotemporal dementia
Background: Familial frontotemporal dementia (FTD) has been associated with mutations in the G4C2 promoter of C9orf72 leading to production of dipeptide protein repeats (DPRs), the most neurotoxic being Glycine‐Arginine (GR). Previous studies have found a parallel relationship with the accumulation of DPRs and a neuroinflammatory response. Specifically, studies have determined microglia proliferation and persistent activation plays a role in disease progression and neurodegeneration. The current study investigated the effect of the bioavailable microbiome derived flavonol metabolite, 3‐hydroxybenzoic acid (3‐HBA) (Wang D. et al, 2015), on microglia morphology and proliferation in mice harboring the AAV9‐GFP(GR)100 virus in the brain recapitulating FTD type neuropathology and behavior.Method: Mice were divided into three groups: GFP control, GR100, and GR100 with 3‐HBA. The GFP control group was transfected with AAV9‐GFP through intra‐cerebroventricular injection, whereas the other two groups were transfected with AAV9‐GFP(GR)100. The virus was administered on postnatal day 0, and the treatment of 3‐HBA began on day 28 for a period of 10 weeks. Immunofluorescence staining of microglia was performed on sections spanning the prelimbic/infralimbic cortex, primary somatosensory cortex (S1), and the hippocampus in order to stereologically quantify microglia proliferation and to reconstruct the microglia in 3D using the imaging software Imaris.Result: Stereological counting determined an increase in microglia density of approximately 40% (p < 0.05) in the S1 of mice transfected with AAV9‐GFP(GR)100. In addition, there was approximately 30% (p < 0.0001) reduction in S1, and hippocampal volume in groups transfected with AAV9‐GFP(GR)100. 3D reconstruction and Sholl analysis determined a change in microglia morphology from a surveilling state, as seen in the GFP control group, to that of activation characterized by increased branching closer to the soma, as observed in the GR100 group. This increased complexity/activation was found to be attenuated with the administration of 3‐HBA which was associated with a significant reduction in branch complexity compared to both the control and GR100 group.Conclusion: This study identifies a novel microbiome derived polyphenol that displayed potential in attenuating microglia activation, and hence reducing the neuroinflammatory response in FTD.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S9)
A novel gut microbiome therapeutic derived from dietary polyphenols attenuates neuroinflammation in vivo in a model of c9orf72 mediated frontotemporal dementia
Background: Frontotemporal dementia (FTD) is a neurodegenerative disorder with various genetic etiologies, the most prevalent of which include G4C2 expansions in the c9orf72 gene. Expansions produce dipeptide repeat proteins (DPR), forming aggregates with deleterious impacts on cellular processes and correlating with neuroinflammation. Glycine‐Arginine (GR) aggregates are the only significantly correlated DPR found in clinically relevant neuroanatomical regions of the brain. Our current study investigates the contribution of innate immunity to FTD pathogenesis and the attenuation of neuropathologies with the brain bioavailable microbiome‐derived metabolite, 3‐hydroxybenzoic acid (3‐HBA).Method: Mice were transfected via intracerebroventricular injection with AAV9‐GFP(GR)100 or AAV9‐GFP and treated starting on Day 28 with either PBS vehicle or 50 mg kg‐1 of 3‐HBA. At 14 weeks mice were sacrificed and frontal cortex (FC), somatosensory cortex (CTX), and hippocampal (HP) tissue was dissected and prepared for RNA sequencing. Differentially expressed genes (DEGs) were identified using DESeq2 and pathway alterations were detected using Ingenuity Pathway Analysis. ELISA for IL‐1β was conducted on FC, CTX, and HP tissue. To determine the ability of 3‐HBA to reduce secretion of IL‐1β, primary microglia pretreated with 3‐HBA were stimulated with LPS+ATP and IL‐1β concentration was analyzed by ELISA.Result: DEGs associated with FTD pathology, protein expression levels of the pro‐inflammatory cytokine IL‐1β, and subsequent amelioration via treatment with 3‐HBA were demonstrated to be a result of contributions from the innate immune system and inflammasome activation in microglia. Inflammatory pathways differentially enriched among treatment groups include TREM1 Signaling, the complement system, and NFκB signaling. GR‐100 Vehicle treated animals exhibited elevated IL‐β in cortical tissue. 3‐HBA was efficacious in vivo in rescuing IL‐1β levels in GR‐100 HBA treated mice to levels of GFP animals. Primary microglia pretreated with 3‐HBA and stimulated with LPS+ATP significantly reduced IL‐1β release, signifying the efficacy of 3‐HBA in attenuating innate immune reactivity.Conclusion: Pathways and genes associated with the innate immune system show enrichment in a model of FTD and are rescued by administration of 3‐HBA. Overexpression of IL‐1β in the cortex of GR‐100 Vehicle animals is attenuated by the administration of 3‐HBA. Our data implicates a gut‐brain axis mechanism of treatment for key FTD associated neuropathologies.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S9)
A novel gut microbiome therapeutic derived from dietary polyphenols attenuates neuroinflammation in vivo in a model of c9orf72 mediated frontotemporal dementia
Background: Frontotemporal dementia (FTD) is a neurodegenerative disorder with various genetic etiologies, the most prevalent of which include G4C2 expansions in the c9orf72 gene. Expansions produce dipeptide repeat proteins (DPR), forming aggregates with deleterious impacts on cellular processes and correlating with neuroinflammation. Glycine‐Arginine (GR) aggregates are the only significantly correlated DPR found in clinically relevant neuroanatomical regions of the brain. Our current study investigates the contribution of innate immunity to FTD pathogenesis and the attenuation of neuropathologies with the brain bioavailable microbiome‐derived metabolite, 3‐hydroxybenzoic acid (3‐HBA).Method: Mice were transfected via intracerebroventricular injection with AAV9‐GFP(GR)100 or AAV9‐GFP and treated starting on Day 28 with either PBS vehicle or 50 mg kg‐1 of 3‐HBA. At 14 weeks mice were sacrificed and frontal cortex (FC), somatosensory cortex (CTX), and hippocampal (HP) tissue was dissected and prepared for RNA sequencing. Differentially expressed genes (DEGs) were identified using DESeq2 and pathway alterations were detected using Ingenuity Pathway Analysis. ELISA for IL‐1β was conducted on FC, CTX, and HP tissue. To determine the ability of 3‐HBA to reduce secretion of IL‐1β, primary microglia pretreated with 3‐HBA were stimulated with LPS+ATP and IL‐1β concentration was analyzed by ELISA.Result: DEGs associated with FTD pathology, protein expression levels of the pro‐inflammatory cytokine IL‐1β, and subsequent amelioration via treatment with 3‐HBA were demonstrated to be a result of contributions from the innate immune system and inflammasome activation in microglia. Inflammatory pathways differentially enriched among treatment groups include TREM1 Signaling, the complement system, and NFκB signaling. GR‐100 Vehicle treated animals exhibited elevated IL‐β in cortical tissue. 3‐HBA was efficacious in vivo in rescuing IL‐1β levels in GR‐100 HBA treated mice to levels of GFP animals. Primary microglia pretreated with 3‐HBA and stimulated with LPS+ATP significantly reduced IL‐1β release, signifying the efficacy of 3‐HBA in attenuating innate immune reactivity.Conclusion: Pathways and genes associated with the innate immune system show enrichment in a model of FTD and are rescued by administration of 3‐HBA. Overexpression of IL‐1β in the cortex of GR‐100 Vehicle animals is attenuated by the administration of 3‐HBA. Our data implicates a gut‐brain axis mechanism of treatment for key FTD associated neuropathologies.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S9)
Defining the role of gut microbiota‐derived ketamine metabolites in Alzheimer’s disease
Background: Ketamine, typically used for providing pain relief and sedation prior to surgical procedures, has recently been recognized as a potential therapy for disorders rooted in neuroinflammation such as major depression. Ketamine undergoes extensive metabolism and characterizing these metabolites is essential to understand the therapeutic efficacy and long‐term effects of ketamine treatment for neuroinflammation. Further, specific enantiomers of ketamine have been shown to specifically alter the composition of the gut microbiota, which through gut‐brain‐axis mechanisms, may contribute to its anti‐inflammatory activity. The objective of this study is to characterize the impact of the gut microbiota on ketamine metabolism and using these metabolites understand how ketamine can be used as a therapeutic for neuroinflammation associated with Alzheimer’s disease (AD).Method: Using an in vitro model of the human gastrointestinal tract, EBIOME we are exploring the impact of ketamine on the human microbiome with metagenomic quantification of gut microbiome species and quantification of ketamine metabolites with UPLC‐MS/MS technology platforms. Ketamine is known to undergo extensive metabolism by liver P450 enzymes, which will interact with the gut microbiome derived metabolites. Hence, following validation in vitro, in ongoing studies ketamine will be chronically dosed into wildtype mice to understand how the gut microbiota‐derived metabolites affect the known liver‐derived secondary metabolites including norketamine and its hydroxylated isomers and dehydrogenated forms.Result: We have evidence in rodents, that ketamine amplifies Lactobacillus, Turicibacter and Sarcina spp. while reducing populations of the opportunistic pathogens Mucispirillim and Ruminococcus indicating that there is a species‐dependent metabolism of ketamine. Bioavailability and acute over chronic pharmacokinetics of these metabolites will be determined in the gut, blood and brain to understand how the gut‐liver metabolic interactions affect chronic ketamine dosing towards understanding the long‐term safety of ketamine.Conclusion: With an understanding of ketamine metabolism, ketamine chronically dosed into 5xFAD AD mouse models we will understand the brain‐bioavailable ketamine metabolites on neuroinflammatory pathophysiologies of AD. Ultimately these studies will help to asses microglia inflammatory activation and Alzheimer’ disease neuropathology.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S9)
Defining the role of gut microbiota‐derived ketamine metabolites in Alzheimer’s disease
Background: Ketamine, typically used for providing pain relief and sedation prior to surgical procedures, has recently been recognized as a potential therapy for disorders rooted in neuroinflammation such as major depression. Ketamine undergoes extensive metabolism and characterizing these metabolites is essential to understand the therapeutic efficacy and long‐term effects of ketamine treatment for neuroinflammation. Further, specific enantiomers of ketamine have been shown to specifically alter the composition of the gut microbiota, which through gut‐brain‐axis mechanisms, may contribute to its anti‐inflammatory activity. The objective of this study is to characterize the impact of the gut microbiota on ketamine metabolism and using these metabolites understand how ketamine can be used as a therapeutic for neuroinflammation associated with Alzheimer’s disease (AD).Method: Using an in vitro model of the human gastrointestinal tract, EBIOME we are exploring the impact of ketamine on the human microbiome with metagenomic quantification of gut microbiome species and quantification of ketamine metabolites with UPLC‐MS/MS technology platforms. Ketamine is known to undergo extensive metabolism by liver P450 enzymes, which will interact with the gut microbiome derived metabolites. Hence, following validation in vitro, in ongoing studies ketamine will be chronically dosed into wildtype mice to understand how the gut microbiota‐derived metabolites affect the known liver‐derived secondary metabolites including norketamine and its hydroxylated isomers and dehydrogenated forms.Result: We have evidence in rodents, that ketamine amplifies Lactobacillus, Turicibacter and Sarcina spp. while reducing populations of the opportunistic pathogens Mucispirillim and Ruminococcus indicating that there is a species‐dependent metabolism of ketamine. Bioavailability and acute over chronic pharmacokinetics of these metabolites will be determined in the gut, blood and brain to understand how the gut‐liver metabolic interactions affect chronic ketamine dosing towards understanding the long‐term safety of ketamine.Conclusion: With an understanding of ketamine metabolism, ketamine chronically dosed into 5xFAD AD mouse models we will understand the brain‐bioavailable ketamine metabolites on neuroinflammatory pathophysiologies of AD. Ultimately these studies will help to asses microglia inflammatory activation and Alzheimer’ disease neuropathology.
- Open Access
- 21 July 2020
- Published by Elsevier in Molecular Immunology
- Vol. 125, 172-177
Characterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes
- 21 July 2020
- Published by Elsevier in Molecular Immunology
- Vol. 125, 172-177
Open AccessCharacterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes
- Open Access
- 9 June 2020
- Published by Springer Nature in Translational Psychiatry
- Vol. 10 (1) , 1-11
Prophylactic effect of flavanol rich preparation metabolites in promoting resilience to a mouse model of social stress
Major depressive disorder (MDD) is a leading cause of disability, and there is an urgent need for new therapeutics. Stress-mediated induction of pro-inflammation in the periphery contributes to depression-like behaviors both in humans and in experimental models. Inflammatory cytokine interleukin-6 (IL-6) has emerged as a potential therapeutic target. Our studies demonstrated that metabolism of flavanol rich cocoa preparation (FRP) led to the accumulation of select phenolic acids that may contribute to its anti-inflammatory activity. Using a repeated social defeat stress (RSDS) model of depression, we showed that oral administration of FRP attenuates susceptibility to RSDS-mediated depression, supporting the further development of FRP as a novel therapeutic for the treatment of stress disorders and anxiety in humans.
- 9 June 2020
- Published by Springer Nature in Translational Psychiatry
- Vol. 10 (1) , 1-11
Open AccessProphylactic effect of flavanol rich preparation metabolites in promoting resilience to a mouse model of social stress
Major depressive disorder (MDD) is a leading cause of disability, and there is an urgent need for new therapeutics. Stress-mediated induction of pro-inflammation in the periphery contributes to depression-like behaviors both in humans and in experimental models. Inflammatory cytokine interleukin-6 (IL-6) has emerged as a potential therapeutic target. Our studies demonstrated that metabolism of flavanol rich cocoa preparation (FRP) led to the accumulation of select phenolic acids that may contribute to its anti-inflammatory activity. Using a repeated social defeat stress (RSDS) model of depression, we showed that oral administration of FRP attenuates susceptibility to RSDS-mediated depression, supporting the further development of FRP as a novel therapeutic for the treatment of stress disorders and anxiety in humans.
- Open Access
- 13 May 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (5) , 760
Peroxisome Proliferator Activator Receptor Gamma Coactivator-1α Overexpression in Amyotrophic Lateral Sclerosis: A Tale of Two Transgenics
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder manifesting with upper and lower neuron loss, leading to impairments in voluntary muscle function and atrophy. Mitochondrial dysfunction in metabolism and morphology have been implicated in the pathogenesis of ALS, including atypical oxidative metabolism, reduced mitochondrial respiration in muscle, and protein aggregates in the mitochondrial outer membrane. Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) plays an essential role in the regulation of mitochondrial biogenesis, the process by which existing mitochondria grow and divide. PGC-1α has been previously reported to be downregulated in the spinal cord of individuals with ALS. Towards targeting PGC-1α as a therapeutic mechanism, we have previously reported improved motor function and survival in the SOD1G93A mouse model of ALS by neuron-specific over-expression of PGC-1α under a neuron-specific enolase (NSE) promoter. As pharmacological intervention targeting PGC-1α would result in whole-body upregulation of this transcriptional co-activator, in the current study we investigated whether global expression of PGC-1α is beneficial in a SOD1G93A mouse model, by generating transgenic mice with PGC-1α transgene expression driven by an actin promoter. Actin-PGC-1α expression levels were assayed and confirmed in spinal cord, brain, muscle, liver, kidney, and spleen. To determine the therapeutic effects of global expression of PGC-1α, wild-type, actin-PGC-1α, SOD1G93A, and actin-PGC-1α/SOD1G93A animals were monitored for weight loss, motor performance by accelerating rotarod test, and survival. Overexpression of actin-PGC-1α did not confer significant improvement in these assessed outcomes. A potential explanation for this difference is that the actin promoter may not induce levels of PGC-1α relevant to disease pathophysiology in the cells that are specifically relevant to the pathogenesis of ALS. This evidence strongly supports future therapeutic approaches that target PGC-1α primarily in neurons.
- 13 May 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (5) , 760
Open AccessPeroxisome Proliferator Activator Receptor Gamma Coactivator-1α Overexpression in Amyotrophic Lateral Sclerosis: A Tale of Two Transgenics
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder manifesting with upper and lower neuron loss, leading to impairments in voluntary muscle function and atrophy. Mitochondrial dysfunction in metabolism and morphology have been implicated in the pathogenesis of ALS, including atypical oxidative metabolism, reduced mitochondrial respiration in muscle, and protein aggregates in the mitochondrial outer membrane. Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) plays an essential role in the regulation of mitochondrial biogenesis, the process by which existing mitochondria grow and divide. PGC-1α has been previously reported to be downregulated in the spinal cord of individuals with ALS. Towards targeting PGC-1α as a therapeutic mechanism, we have previously reported improved motor function and survival in the SOD1G93A mouse model of ALS by neuron-specific over-expression of PGC-1α under a neuron-specific enolase (NSE) promoter. As pharmacological intervention targeting PGC-1α would result in whole-body upregulation of this transcriptional co-activator, in the current study we investigated whether global expression of PGC-1α is beneficial in a SOD1G93A mouse model, by generating transgenic mice with PGC-1α transgene expression driven by an actin promoter. Actin-PGC-1α expression levels were assayed and confirmed in spinal cord, brain, muscle, liver, kidney, and spleen. To determine the therapeutic effects of global expression of PGC-1α, wild-type, actin-PGC-1α, SOD1G93A, and actin-PGC-1α/SOD1G93A animals were monitored for weight loss, motor performance by accelerating rotarod test, and survival. Overexpression of actin-PGC-1α did not confer significant improvement in these assessed outcomes. A potential explanation for this difference is that the actin promoter may not induce levels of PGC-1α relevant to disease pathophysiology in the cells that are specifically relevant to the pathogenesis of ALS. This evidence strongly supports future therapeutic approaches that target PGC-1α primarily in neurons.